MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients

MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients

20 April 2015

Melanoma Institute Australia and its key affiliate, Crown Princess Mary Cancer Centre Westmead were the highest recruiting centre worldwide for the study into the immunotherapies pembrolizumab versus ipilimumab, in advanced melanoma, with the findings published in the New England Journal of Medicine, the leading medical journal in the world.

The study found that the anti–PD-1 antibody pembrolizumab (trade name KEYTRUDA®) prolonged survival, and had less high-grade toxicity, compared with ipilimumab (trade name YERVOY®) in patients with advanced melanoma, that is, melanoma that has spread to distant parts of the body.

Associate Professor Georgina Long from Melanoma Institute Australia and University of Sydney said, “Here at MIA and Westmead we have been undertaking clinical trials with immunotherapy treatment using anti-PD-1 drugs for over three years, and these findings are the final piece of data that show the anti–PD-1 antibody pembrolizumab is better than current treatments for patients with advanced melanoma.”

The immune checkpoint inhibitor, ipilimumab, is one of the standard treatments for patients with advanced melanoma. The latest findings show that pembrolizumab, which inhibits the programmed death receptor 1 (PD-1) immune checkpoint on immune T cells, has antitumor activity: that is, it reduces the size of the tumours in patients with advanced melanoma in approximately 70% of patients, with deep reduction in over 30%, and prolongs survival compared with ipilimumab.

This clinical trial using pembrolizumab (KEYTRUDA®) recorded a 1 year survival rate of 74%, whilst those who received ipilimumab (YERVOY®) had a 1 year survival rate of 58%. Five years ago, only 30-35% of patients with advanced melanoma survived 1-year.

“These results are world-first, where two effective immunotherapies are directly compared, and we significantly improve outcomes for patients even further. This is great news for Australia, which has the highest incidence of melanoma in the world, and an Australian dies from this disease every 6 hours” said Assoc Prof Georgina Long. “This is evidence which will be considered by bodies around the world, including the Australian Government, to make these drugs accessible to all melanoma patients".

Research Co-Director of Melanoma Institute Australia and Macquarie University Professor Rick Kefford claims, “this breakthrough is probably the most important development in the treatment of this disease ever, and a landmark in terms of cancer treatment in general.”

Others Australian centres involved in this trial include: Newcastle Melanoma Unit, NSW; The Austin Hospital, VIC; Sir Charles Gardiner Hospital, WA; Princes Alexandra Hospital, QLD; Sydney Cancer Centre, RPAH, NSW.

 

Highlights in melanoma research from ESMO
21 Sep 2017

Highlights in melanoma research from ESMO

The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.

Australian researchers stopping melanoma in its tracks
11 Sep 2017

Australian researchers stopping melanoma in its tracks

Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.

Virus-antibody combo shows promise for treating advanced melanoma
08 Sep 2017

Virus-antibody combo shows promise for treating advanced melanoma

A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.

It's time to outlaw sunburn on reality TV shows - enough is enough
31 Jul 2017

It's time to outlaw sunburn on reality TV shows - enough is enough

It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.

Identifying markers for optimal response
28 Jul 2017

Identifying markers for optimal response

Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?

Global Melanoma Research Report - July
20 Jul 2017

Global Melanoma Research Report - July

In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.

A day in the life of... Sarah Lane
14 Jul 2017

A day in the life of... Sarah Lane

Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process. 

Differentiating moles from melanoma
14 Jul 2017

Differentiating moles from melanoma

Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.

Introducing SunSense Sunscreen
11 Jul 2017

Introducing SunSense Sunscreen

We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business. 

Identifying hidden melanoma
07 Jul 2017

Identifying hidden melanoma

New MIA research revealed dermoscopy features that can help detect desmoplastic melanoma.

60 Minutes' MIA Patient Feature Program
04 Jul 2017

60 Minutes' MIA Patient Feature Program

Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here

Training our future melanoma experts
22 Jun 2017

Training our future melanoma experts

Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.

Update from ASCO 2017
17 Jun 2017

Update from ASCO 2017

Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.

Diagnosing melanoma of the mouth
16 Jun 2017

Diagnosing melanoma of the mouth

MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.

New practice-changing research will reduce the need for major surgery in many melanoma patients
09 Jun 2017

New practice-changing research will reduce the need for major surgery in many melanoma patients

New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.

MIA researchers to share new findings at world's largest cancer conference
25 May 2017

MIA researchers to share new findings at world's largest cancer conference

Researchers from MIA will present their latest research findings to the world’s largest oncology conference in early June.

Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours
18 May 2017

Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours

Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.

Melanoma March 2017 wraps up!
12 May 2017

Melanoma March 2017 wraps up!

Melanoma March 2017 - that's a wrap! Thank you to everyone that helped make it happen. 

Melanoma March 2017 helping kick start the Big Data for Melanoma national Research Project!
11 May 2017

Melanoma March 2017 helping kick start the Big Data for Melanoma national Research Project!

Thank you so much to all those who contributed in a variety of ways to Melanoma March 2017 in 17 different locations and more around the country! You have contributed to getting the Big Data for Melanoma national Research Project happening!

Whole genome sequencing finds unexpected genomic landscape in melanoma
10 May 2017

Whole genome sequencing finds unexpected genomic landscape in melanoma

By looking at the ‘dark matter’ of the genome, new research has found that genetic changes in acral and mucosal melanoma are completely different to mutations found in skin melanoma.